Skip to main content

Alport Syndrome clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for
  • Atrasentan in Patients With Proteinuric Glomerular Diseases

    Sorry, in progress, not accepting new patients

    The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

    Glendale, California and other locations

Our lead scientists for Alport Syndrome research studies include .

Last updated: